Overview
CYFRA 21-1 is a tumor marker derived from cytokeratin 19 fragments, as explained in the document. Cytokeratin 19 is a structural protein found in epithelial cells, and its soluble fragment, CYFRA 21-1, is released into the bloodstream during cell death or tumor lysis. CYFRA 21-1 is especially significant in the management of non-small cell lung cancer (NSCLC) and is considered a sensitive marker for squamous cell carcinoma of the lung.
The document highlights that CYFRA 21-1 is detectable in serum and is commonly used for diagnosis, prognosis, therapy monitoring, and detection of disease recurrence. Elevated levels reflect tumor burden and disease progression. Although it is not recommended for population screening, CYFRA 21-1 plays an important role in clinical decision-making when used alongside imaging and other tumor markers.
Symptoms
CYFRA 21-1 itself does not cause symptoms. Symptoms arise from the underlying lung malignancy or related conditions associated with elevated levels, as outlined in the document.
Common symptoms associated with lung cancer may include:
- Persistent cough
- Chest pain
- Shortness of breath
- Fatigue and weakness
- Unexplained weight loss
Additional symptoms may include:
- Coughing up blood
- Hoarseness
- Recurrent respiratory infections
- Loss of appetite
The document also notes that these levels may be mildly elevated in certain benign lung conditions, where symptoms such as fever, cough, or breathlessness may be present. Because symptoms are nonspecific, laboratory evaluation using it helps support clinical assessment rather than replace it.
Causes
According to the document, elevated CYFRA 21-1 levels occur due to increased breakdown of epithelial tumor cells, leading to the release of cytokeratin 19 fragments into circulation.
Primary causes include:
- Non-small cell lung cancer
- Squamous cell carcinoma of the lung
- Tumor progression or metastasis
- Tumor cell death following therapy
The document also identifies non-malignant causes that may lead to mild elevations, including:
- Chronic obstructive pulmonary disease
- Pneumonia
- Pulmonary fibrosis
- Liver disease
- Renal failure
- Mesothelioma
- Extrapulmonary malignancies
These conditions highlight the importance of interpreting CYFRA 21-1 levels in the appropriate clinical context.
Risk Factors
Risk factors for elevated CYFRA 21-1 levels are closely linked to lung cancer and epithelial malignancies, as described in the document.
Major risk factors include:
- Diagnosed or suspected non-small cell lung cancer
- Squamous cell carcinoma of the lung
- Advanced or metastatic disease
- Disease recurrence after therapy
Additional risk factors include:
- Chronic lung diseases such as COPD
- Pulmonary infections or fibrosis
- Renal or hepatic dysfunction
- History of epithelial cancers
The document emphasizes that higher CYFRA 21-1 levels correlate with increased tumor burden, advanced stage, and poorer prognosis, making it a valuable prognostic indicator rather than a screening test.
Prevention
CYFRA 21-1 elevation cannot be directly prevented, as it reflects underlying disease processes rather than an isolated condition. However, the document outlines preventive and best-practice strategies aimed at early detection, accurate monitoring, and improved clinical outcomes.
Preventive measures include:
- Early diagnostic evaluation in patients with suspected lung malignancy
- Regular monitoring of CYFRA 21-1 levels during and after therapy
- Using CYFRA 21-1 in combination with other tumor markers such as CEA, NSE, or SCC antigen
- Close follow-up to detect relapse or metastasis
For accurate testing, the document emphasizes:
- Collection of 3 mL of plain blood in a red-capped or serum separator tube
- Allowing blood to clot completely before serum separation
- Separating serum within 2 hours of collection
- Refrigerated storage during transport
- Avoiding hemolyzed, lipemic, or icteric samples
